Press releases

Sam Leno will join the Company as Chief Financial Officer (CFO) and Executive Vice President of Finance and Information Systems

SYNTAX is the first trial to compare the results of drug-eluting stents with those of cardiac surgery in the most complex patient subsets

A live webcast and replay of the May 2 conference session will be available

"I am pleased we came in at the upper end of our ranges for sales and EPS for the quarter," said Jim Tobin, President and Chief Executive Officer

Product provides enhanced control for accessing desired vessel location

A live webcast and replay of the April 23 conference call will be available.

Company has resolved deficiencies in the warning letter issued by the U.S. Food and Drug Administration (FDA) to the Guidant Corporation

Company plans to launch the product after reimbursement approval is granted

Trial is designed to identify and investigate clinically relevant endpoints for evaluating the efficacy and durability of endovascular treatment of brain aneurysms

BTK CHILL study demonstrates high rate of limb protection at one year

TAXUS® Express2™ paclitaxel-eluting coronary stent system met its primary endpoint in the treatment of in-stent restenosis

Two-year review of TAXUS Stent safety data presented at ACC

Results reaffirm strength of Boston Scientific's dual drug-eluting stent program

Compliance program is the first of its kind in the medical device industry; is expected to launch in the United States later this year

Smallest Dual Chamber System offered in Japan provides enhanced therapies to patients at risk of sudden cardiac death

Company to host analyst meeting and symposium on drug-eluting stents

A live webcast and replay of the March 19 conference session will be available

IPO would involve Boston Scientific selling approximately 20 percent of the Endosurgery group and establishing a separately traded public company

Boston Scientific Corporation (NYSE: BSX) today announced several enhancements related to the governance of the company. "Boston Scientific is...

A live webcast and replay of the March 13 conference session will be available

Company looks forward to providing the Committee the information it has requested relating to TAXUS® paclitaxel-eluting coronary stents

Campaign spokesperson - a Formula race car driver, amputee, and chronic pain patient - to promote public awareness

Swedish registry further illustrates the strengths and weaknesses of so-called "real-world" registries when compared to prospective, randomized and actively controlled trials

Articles scheduled for publication in the March 8th edition confirm the safety and efficacy of TAXUS® Express2™ paclitaxel-eluting coronary stent system

DES patients have significantly lower rates of death, heart attack and re-intervention than BMS patients

Company supports the proposed expansion but also supports broader coverage

Company provides guidance for first quarter 2007December 31, 2006, as well as...

Company will webcast its conference call discussing financial results for the fourth quarter and the year ended December 31, 2006 on Thursday, February 1, at 8:30 a.m.

Boston Scientific Corporation (NYSE: BSX) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to expand its...

The live webcast and archived replay of the Thursday, February 1 call will be available

New U.S. shelf life is longer than any competing drug-eluting stent product

Court orders injunction and damages

U.K. Court of Appeal affirmed an earlier ruling to revoke the U.K. version of a European paclitaxel stent patent owned by Angiotech Pharmaceuticals, Inc.

Lower rates of re-intervention and major adverse events reported for the TAXUS Stent in study of diabetic patients

Boston Scientific only company to offer two distinct drug-eluting stent platforms

Boston Scientific Corporation (NYSE: BSX) today announced preliminary, unaudited net sales for its fourth quarter and full year ended December 31,...

Plan to increase innovation, productivity and competitiveness

Acquisition demonstrates Company's commitment to leadership in treating carotid artery disease

A live webcast and replay of the Tuesday, January 9th session will be available

Trial highlights the importance of appropriate pacing for patients at risk of sudden cardiac death

To date, no product complaints have been reported to Boston Scientific related to this issue, and there have been no reported injuries

Device now cleared for use in both carotid arteries and saphenous vein grafts

Data from 7000 TAXUS patients showed substantial benefits in keeping arteries open and avoiding repeat procedures

Data presented to a panel of experts assembled by the FDA in response to concerns about the incidence of late stent thrombosis in drug-eluting stents

A live webcast and replay of the November 29 session will be available

Becker will be responsible for managing the Company's global government affairs function, as well as its corporate public policy and political action committee

Lower re-intervention rates for the TAXUS Stent in diabetic patients

LATITUDE Patient Management is the first and only remote monitoring system to provide clinicians with direct device data integration capability into GE's Centricity Electronic Medical Record (EMR)

A replay of the webcast of today's analyst meeting will be archived and available in the Investor Relations section of the Company's website

Important and growing diabetic patient subset accounts for more than one-quarter of all coronary interventional procedures in the United States

Technology serves as second-generation platform for Company's market-leading TAXUS® paclitaxel-eluting coronary stent system

Company to acquire EndoTex

Innovative technology makes Precision™ spinal cord stimulator accessible to more patients

Brennan comes to the position with over 10 years’ experience at Boston Scientific; will be responsible for all aspects of investor relations

A live webcast and replay of the November 6 presentations will be available at Boston Scientific's website

Thousands of heart failure patients are now eligible for additional pacing feature

Zelenkofske to lead development and implementation of pre- and post-market clinical strategy that supports Company's CRM technology and therapy portfolio

Positive results also reported for TAXUS Liberte stent direct stenting

Results were announced at the Cardiovascular Research Foundation's (CRF) eighteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, in Washington, D.C.

Results also show statistically significant late stent thrombosis rate for Cypher® stent vs. bare-metal stent

Two-year results continue to evaluate long-term safety and efficacy

Multi-center registry to enroll 10,000 patients over two years

Study of 1,558 patients was designed to retrospectively compare one-year clinical outcomes in real-world practice

"In Q3 we were able to achieve results near the high end of our previously announced preliminary sales and earnings ranges," said Jim Tobin, President and CEO

Results to include new data on next-generation TAXUS® Liberte™ Stent System

MAPS trial demonstrates Company's commitment to understanding the efficacy and durability of endovascular therapies for the treatment of brain aneurysms

Boston Scientific Corporation (NYSE: BSX) announced today that the PROMUS™ Everolimus-Eluting Coronary Stent System has received CE Mark...

Victory supports previous court decisions related to the suit Medtronic filed against Guidant in August 2003

A live webcast and replay of the October 18 conference call will be available

FDA approval makes remote monitoring available by more than 150,000 additional patients

Gobierno de Puerto Rico aprueba el Sistema Precision, que brinda a los médicos una nueva opción de tratamiento para dolor agudo y crónico

Plans for changes consistent with HRS guidelines includes Company's commitment to the development of independent, industry-wide oversight to facilitate consistent communications, surveillance and product performance reporting practices

New cochlear implant technology to significantly increase hearing potential and quality of life for the severe-to-profoundly deaf.

CryoPlasty® Therapy may be an alternative to surgery or limb amputation

“We made progress on a number of fronts, most notably the integration of Guidant and our quality initiatives," said Jim Tobin, President and CEO.

FLEXView™ System enables physicians to perform less-invasive cardiac surgical ablation procedures

Company welcomes FDA statement that drug-eluting stents remain safe and effective when used for approved indications

NEJM editorial and articles describe results of two randomized clinical trials, PASSION and TYPHOON

Boston Scientific Corporation (NYSE: BSX) today announced four-year follow-up data from its TAXUS II paclitaxel-eluting stent system...

Initial six-month results show positive outcomes in diabetic patients; safety events for diabetic subset lower than overall patient population

International data suggests low revascularization rates for both TAXUS stent and PROMUS™ (XIENCE™ V) stent

PROMUS Stent joins market-leading TAXUS® Paclitaxel-Eluting Coronary Stent Systems

Results expected to continue to support safety and performance of Boston Scientific's second-generation drug-eluting stent system

Company also to host WCC symposia on drug-eluting stents, therapies in cardiac rhythm management and carotid artery disease

"The second quarter was a transforming one for Boston Scientific," said Jim Tobin, President and CEO

Precision™ SCS System, the first and smallest rechargeable system, achieves rapid adoption

Initial six-month results consistent with previous TAXUS registries

New system enhances diagnosis and treatment of blocked vessels and heart disorders

New Jaw Configuration Designed to Yield Larger Tissue Specimens and Improve Procedural Outcomes

Young will be responsible for all quality assurance and reliability functions for the CRM Group, including product performance reporting

A live webcast and replay of the Thursday, July 27 conference call will be available

Report analyzed data from nearly 23,000 U.S. patents and 9,000 U.S. patent applications

Company is providing safety information and retrieving a specific subset of pacemakers, cardiac resynchronization pacemakers and implantable cardioverter defibrillators

A live webcast and replay of the June 27 conference session will be available

Jury had found that J&J's Cypher® stent product infringed a Boston Scientific drug coating patent

Boston Scientific's TAXUS stent system used in more complex lesions than J&J's Cypher

A live webcast and replay of the June 13 conference session will be available

Company plans to use the net offering proceeds for general corporate purposes

Company expects to receive the offering proceeds upon closing on June 9, 2006

Technology features powerful combination of deliverability and trackability to enhance clinical versatility